RecruitingPhase 1Phase 2NCT05320198

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Sponsor

Disc Medicine, Inc

Enrollment

150 participants

Start Date

Jun 6, 2022

Study Type

INTERVENTIONAL

Conditions

Myelodysplastic Syndromes Myelofibrosis Anemia Primary Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Myelofibrosis; Anemia Myelofibrosis Due to and Following Polycythemia Vera

Summary

This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DISC-0974 for people with anemia, myelodysplastic syndromes, and other related conditions. The study is currently recruiting participants at 25 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDISC-0974

DISC-0974 is administered subcutaneously.

Locations(28)

Banner MD Anderson

Gilbert, Arizona, United States

City of Hope - Duarte

Duarte, California, United States

City of Hope - Lennar

Irvine, California, United States

University of California, San Francisco

San Francisco, California, United States

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Sylvester Cancer Center - U Miami

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory Winship Cancer Institute

Atlanta, Georgia, United States

University of Michigan

Ann Arbor, Michigan, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Washington University St.Louis

St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Montefiore

New York, New York, United States

Atrium Health Wake Forest Baptist

Winston-Salem, North Carolina, United States

Gabrail Cancer Center Research

Canton, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

The Ohio State University

Columbus, Ohio, United States

Oregon Health and Science University

Portland, Oregon, United States

Sargon Research - Pennsylvania Cancer Specialists and Research Center

Gettysburg, Pennsylvania, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

MD Anderson

Houston, Texas, United States

University of Washington

Seattle, Washington, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Linear Clinical Research

Nedlands, Australia

St. Vincent's Hospital

Sydney, Australia

Perth Blood Institute

West Perth, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05320198

Related Trials

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT063031931 location

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

NCT053507481 location

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

NCT055881541 location

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

NCT054830101 location

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480156 locations